Press Releases

GAITHERSBURG, Md. , July 15, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the closing of the previously announced acquisition of Spitfire Pharma, Inc. , including the product candidate ALT-801, a potent GLP-1/Glucagon receptor

Company to receive rights to novel GLP-1/glucagon dual agonist that addresses obesity and metabolic dysfunction, primary causes of NASH Greater impact on liver fat, inflammation and fibrosis compared to leading NASH candidates in established preclinical models Altimmune plans to advance the drug

GAITHERSBURG, Md. , June 12, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced it has appointed Will Brown as Chief Financial Officer. Mr. Brown has been serving as the Acting Chief Financial Officer since May 2018 .

Meeting on HepTcell Phase 2 program for treatment of chronic hepatitis B (HBV) GAITHERSBURG, Md. , June 10, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it successfully completed a pre-IND (Investigational New Drug) meeting

GAITHERSBURG, Md. , June 05, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biotechnology company, today announced that it has received additional patent protection for its HepTcell and ALT-702 programs in the United States . “We are pleased to strengthen our intellectual

Conference Call & Webcast Scheduled for Wednesday, May 15, at 8:30am Eastern Time GAITHERSBURG, Md. , May 14, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced financial results for the first quarter ended March 31, 2019 and

GAITHERSBURG, Md. , May 08, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the first quarter ended March 31, 2019 before the market open and host a conference call on Wednesday, May 15,

Dr. Sybil Tasker to present on April 16 at 12:55pm Eastern Time GAITHERSBURG, Md. , April 11, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced an oral presentation at the World Vaccine Congress being held in Washington D.C.

Conference call and webcast scheduled for tomorrow, Tuesday, April 2, at 8:30 am Eastern Time GAITHERSBURG, Md. , April 01, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced financial results for the year ended December 31, 2018 ,

GAITHERSBURG, Md. , March 21, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage immunotherapeutics company, today announced that it will announce financial results for the year ended December 31, 2018 before the market open and host a conference call on Tuesday, April 2, 2019